Skip to content
AnalystLens
Back to MRNABalance Sheet

Moderna, Inc. Cash & Equivalents 2015-2026 | MRNA

Annual FY2015–FY2025 · quarterly through Q1 FY2026

Latest annual · FY2025

$2.60B

+34.7%YoY vs FY2024Source: 10-KFY2025

From $159.0M in FY2015 to $2.60B in FY2025: 16.3× in 10 years.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$1.9B+17.6%Not reportedNot reportedNot reported
FY25$1.6B−20.9%$1.3B−48.4%$1.1B−31.1%$2.6B+34.7%
FY24$2.1B−40.7%$2.5B−35.2%$1.6B−44.3%$1.9B−34.2%
FY23$3.5B−31.4%$3.8B+33.0%$3.0B−2.4%$2.9B−8.6%
FY22$5.0B−7.4%$2.9B−48.8%$3.0B−45.6%$3.2B−53.3%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Key Statistics

Trend DirectionStable
CAGR

−0.3%

FY2020
$2.64B
FY2025
$2.60B

5 years selected · on the chart

01—History

Cash & Equivalents History

Year-over-year comparison from 10-K annual reports

  11. $2.60B
YoY changeLargest recent move+1016.9%in FY20Latest +34.7%

4 older moves run past ±150% (largest +1016.9%); point at, tap or drag across the bars to read one.

02—Ledger

Cash & Equivalents, period by period

PeriodValueChangeSource
FY2025$2.60B+34.7%10-K
FY2024$1.93B−34.2%10-K
FY2023$2.93B−8.6%10-K
FY2022$3.21B−53.3%10-K
FY2021$6.86B+160.2%10-K
FY2020$2.64B+1016.9%10-K
FY2019$236.0M−64.2%10-K
FY2018$658.4M+388.2%10-K
FY2017$134.9M+169.3%10-K
FY2016$50.1M−68.5%10-K
FY2015$159.0M—10-K

03—Questions

What is cash & equivalents?

Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.

What is Moderna, Inc.'s current cash & equivalents?

Moderna, Inc. (MRNA) annual cash & equivalents for 2025 was $2.60B, a 34.67% increase from 2024. Moderna, Inc. cash & equivalents for the quarter ending March 31, 2026 was $1.91B.

What was Moderna, Inc.'s cash & equivalents in 2024?

Moderna, Inc. annual cash & equivalents for 2024 was $1.93B, a 34.19% decline from 2023.

What was Moderna, Inc.'s cash & equivalents in 2023?

Moderna, Inc. annual cash & equivalents for 2023 was $2.93B, a 8.64% decline from 2022.

What is Moderna, Inc.'s 5-year cash & equivalents CAGR?

Moderna, Inc. cash & equivalents grew at a compound annual growth rate (CAGR) of 0.31% from FY2020 to FY2025, going from $2.64B to $2.60B over 5 years.

Company
Moderna, Inc.
Ticker
MRNA
Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)
View company profile →